Trexquant Investment LP cut its position in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 21.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,325 shares of the biopharmaceutical company’s stock after selling 1,975 shares during the quarter. Trexquant Investment LP’s holdings in Portola Pharmaceuticals were worth $396,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Portola Pharmaceuticals by 14.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 258 shares during the last quarter. Jacobi Capital Management LLC acquired a new stake in Portola Pharmaceuticals during the second quarter worth about $125,000. IFP Advisors Inc increased its stake in Portola Pharmaceuticals by 7.7% during the second quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 170 shares during the last quarter. QS Investors LLC acquired a new stake in Portola Pharmaceuticals during the second quarter worth about $147,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Portola Pharmaceuticals during the third quarter worth about $178,000. Institutional investors own 87.45% of the company’s stock.
Shares of Portola Pharmaceuticals Inc (NASDAQ PTLA) opened at $53.93 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31. Portola Pharmaceuticals Inc has a 12 month low of $17.15 and a 12 month high of $67.10.
PTLA has been the subject of several research analyst reports. Zacks Investment Research lowered Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Credit Suisse Group set a $70.00 target price on Portola Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 10th. They noted that the move was a valuation call. BidaskClub lowered Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 19th. Oppenheimer reiterated a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research note on Wednesday, September 6th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $71.15.
WARNING: This piece of content was reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/04/portola-pharmaceuticals-inc-ptla-shares-sold-by-trexquant-investment-lp.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).
Receive News & Ratings for Portola Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.